NSCLC (Advanced Non-small Cell Lung Cancer)

Oncology
6
Pipeline Programs
7
Companies
5
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
1100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

MaaT Pharma
MaaT PharmaFrance - Lyon
1 program
1
MaaT033 capsulePhase 2
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
MaaT033 capsulePhase 21 trial
Active Trials
NCT07001618Not Yet Recruiting162Est. Sep 2032
BlossomHill Therapeutics
1 program
1
BH-30643Phase 1/21 trial
Active Trials
NCT06706076RecruitingEst. Jul 2029
DS
Daiichi SankyoChina - Shanghai
1 program
1
U3-1287Phase 1/21 trial
Active Trials
NCT01211483Completed222Est. Nov 2013
ALX Oncology
ALX OncologyCA - South SF
1 program
1
ALX2004Phase 11 trial
Active Trials
NCT07085091RecruitingEst. Dec 2027
Precision BioSciences
1 program
1
CEA-targeted CAR-TPhase 1Cell Therapy1 trial
Active Trials
NCT07250386Recruiting48Est. Sep 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
RegeneronMaaT033 capsule
BlossomHill TherapeuticsBH-30643
Daiichi SankyoU3-1287
Precision BioSciencesCEA-targeted CAR-T
ALX OncologyALX2004

Clinical Trials (5)

Total enrollment: 432 patients across 5 trials

NCT07001618RegeneronMaaT033 capsule

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Start: Sep 2025Est. completion: Sep 2032162 patients
Phase 2Not Yet Recruiting
NCT06706076BlossomHill TherapeuticsBH-30643

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Start: Jan 2025Est. completion: Jul 2029
Phase 1/2Recruiting
NCT01211483Daiichi SankyoU3-1287

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Start: Sep 2010Est. completion: Nov 2013222 patients
Phase 1/2Completed
NCT07250386Precision BioSciencesCEA-targeted CAR-T

A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors

Start: Oct 2025Est. completion: Sep 202848 patients
Phase 1Recruiting
NCT07085091ALX OncologyALX2004

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Start: Aug 2025Est. completion: Dec 2027
Phase 1Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 432 patients
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)